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Aims: We wanted to pinpoint any differences in treatment between participating
nursing homes, investigate which drugs are currently prescribed most frequently for
long-term patients in nursing homes, estimate prevalence of administration for the
following drug groups: neuroleptics, antidepressants, antidementia agents, opioids
and the neuroleptics/anti-Parkinson’s drug combination, and study comorbidity cor-
relations. We also wanted to study differences in the administration of medications to
patients with reduced cognitive functions in relation to those with normal cognition.
Methods: Information about 513 patients was collected from seven nursing homes in
the city of Bergen, Norway, during the period March–April 2008. This consisted of
copying personal medication records, weighing, recording the previous weight from
records, electrocardiography, anamnestic particulars of any stroke suffered, recording
if there is cognitive impairment or not and analyzing a standardized set of blood
samples. Results: Considerable treatment differences existed between nursing
homes, both percentage patients and Defined Daily Dosages. Patients with reduced
cognitive functions were prescribed less drugs in general, except neuroleptics. Of all
patients, 41.5% were given antidepressants, 24.4% neuroleptics, 22.0% benzodiaze-
pines, 8.0% anticholinesterases and 5.0% memantine. The ratio of traditional to aty-
pical neuroleptics was 122:23. In all, 30.0% of the patients taking neuroleptics were on
more than one drug and 35.0% of the patients had opioids by way of regular or as-
needed drugs, ratio 14.6%:28.7%. Of 146 patients on neuroleptics, five patients had
anti-Parkinson’s drugs too. The average use of regular drugs for patient with intact
cognition was 7.1 drugs, and for patients with reduced cognitive functions 5.7 drugs.
Conclusions: There are differences in treatment with psychoactive drugs between
nursing homes. Patients with reduced cognitive functions receive less cardiovascular
drugs than patients with normal cognition. The reason for this still remains unclear.
Improvement strategies are needed. The proportion of patients per institution on
selected drugs can serve as a feedback parameter in quality systems.
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Background
Norway has 4.6 million inhabitants, 55 public
hospitals, 41 052 nursing home beds and 1796 beds
in old people’s homes, 96.8% of nursing home
beds are in single rooms and 43.3% of all deaths
(total 41 342) are in nursing institutions (Statistics
Norway, 2010). The health care system is split in
first- and second-line services. The second line
contains the 55 hospitals and specialist services
(included private specialists). Second line is
administered and financed directly from the state.
First-line services are administered and financed
by the municipalities (n5 431). First line covers
general practice services, mother and child care,
home care and nursing homes (n5 900).
The high consumption of psychopharmaceu-
ticals in nursing homes has been emphasized in a
number of studies and the prevalence of psy-
choactive drugs has been well documented earlier,
but some years ago (Ruths et al., 2001; Ranhoff and
Brors, 2005; Selbaek et al., 2008). Few authors have
placed the emphasis on treatment differences
between nursing homes and the general differences
in medication of patients suffering dementia as
opposed to non-demented nursing home patients
(Nygaard et al., 2003).
The high drug consumption among elderly
people over 65 is problematic. On average, the
elderly nursing home residents in Bergen had five
drugs each some years ago (Nygaard et al., 2003).
In a study of drug consumption at five smallish
nursing homes in Norway, drug consumption was
found to be greatest within drugs for ‘digestive
organs and metabolism’, ‘blood and blood-forming
organs’, ‘heart and circulation’, ‘urogenital system
and sex hormones’ and ‘nervous system’ (Nygaard,
2001).
Polypharmacy has usually been defined as
the use of five or more drugs (Hunska˚r, 2003).
Polypharmacy is the most important risk factor
for drug side effects and increases the risk of drug
interactions (Fastbom, 2001; Johnell and Klarin,
2007).
The elderly are particularly vulnerable to the
side effects of psychopharmaceuticals, and antic-
holinergic burden involves a risk of delirium
(Turnheim, 2000). Use of long-acting benzodia-
zepines can be one of the causes of falls in
patients over 65 years of age (Blain et al., 2000).
Concurrent use of three or more psychopharma-
ceuticals has been found to be associated with the
risk of falling (Gales and Menard, 1995).
In the BEDNURS (The Bergen district nursing
home) study, 23% of the patients suffering from
dementia, nursing home population in Bergen,
Norway, were found to be on antipsychotics (Ruths
et al., 2001). Double-blind studies have shown little
symptom reduction connected with the use of anti-
psychotics as compared with placebo (Druckenbrod
et al., 1993; Jeste et al., 2008). Of 27 patients, 23 fare
well or better without antipsychotics (Ruths et al.,
2001). In particular, conventional antipsychotics are
associated with extra pyramidal side effects, like
drug-induced Parkinsonism (Tison et al., 1999; Saltz
et al., 2000). Both atypical and conventional anti-
psychotics are associated with a significantly greater
mortality risk than placebo. The greatest increase in
mortality occurred among people taking higher
(above median) doses of conventional antipsychotic
medications (Wang et al., 2005).
We wanted to pinpoint any differences in treat-
ment between participating nursing homes, investi-
gate which drugs are currently prescribed most
frequently for long-term patients in nursing homes,
estimate prevalence of administration for the fol-
lowing drug groups: neuroleptics, antidepressants,
antidementia agents, opioids and the neuroleptics/
anti-Parkinson’s drug combination, and study
comorbidity correlations. We also wanted to study
differences in the administration of medication
for patients with reduced cognitive functions in
relation to patients with normal cognition.
The study was approved by the Regional Ethics
Committee of Western Norway.
Methods
Bergen has , 250 000 inhabitants and 37 nursing
homes (2300 beds). Bed numbers range from 20
to 189. Seven nursing homes participated in this
study. Participating nursing homes were selected
on the basis of a relative similarity of functions,
county ownership (no private institutions) and
physician staffing. Nursing home characteristics
are presented in Table 1. Only long-term patients
(n5 513) were included. Sufficient information
was available for all patients and they were all
included in the analyses.
Information about the patients was gathered
during the period between March and April 2008.
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Twenty-four medical students conducted the data
collection, which consisted of copying medi-
cation cards (information about drug names, if
regular or as-needed, prescription and dosage),
weighing, details of any stroke suffered and
degree of cognitive impairment. Electrocardio-
graphy was conducted to diagnose atrial fibrilla-
tion and a standardized set of blood samples was
analyzed.
In order to group the material into patients
with/without cognitive impairment, we used the
Berger scale (Berger, 1980) and recorded patient
information. A caregiver who knew the patient
decided between six ‘level descriptions’ of cog-
nitive impairment, thus rating the degree of
severity as a score from 0 to 6. The method was
validated by comparing the extent to which drugs
for dementia were given to patients scoring above
0, giving a 95% overlap.
The recorded data were keyed into Excel and
the drugs were coded according to the Anatomi-
cal Therapeutic Chemical (ATC) Drug Register
(Skrbo et al., 2004). For each drug, the students
punched in the full ATC code, dosage, number
of times per day given, total daily dosage and
whether regular/as-needed. For the psychoactive
drugs, which are part of the comparison between
institutions, Defined Daily Dosages (DDDs) were
registered (except for opioids being part of codine–
paracetamol combination drugs). To compare
the total use of psychoactive drugs (hypnotics,
anxiolytics, antidementia drugs, neuroleptics and
opioids) between institutions, we used the calcu-
lated parameter: [(Drug DDD)3 (% of patients
in institution on drugs of drug-class)]. Straight
counts were performed in Excel, but for statistical
analyses JMP 8 was generally used. Means and
standard deviations (SD) are reported. To analyze
differences in the average between multiple
groups for continuous data, the Tukey–Kramer
(Honestly Significant Difference) multiple com-
parison procedure was used as a parametric
method and the Kruskal–Wallis analysis of var-
iance (ANOVA) as a non-parametric method. For
analyzing ordinal and nominal data, the Pearson
x2 test was used and the results are reported as
odds ratios (OR) with 95% confidence intervals
(CIs). All tests were done at significance level
0.05. To search for factors with potential impact
on prescription rates, we conducted a multinomial
logistic regression analysis, and to adjust for
differences in patient and nursing home character-
istics we performed a two-way ANOVA.
Results
The nursing homes were comparable in terms of
nursing staff (county standard), financing (public,
not private) and residents’ gender distribution
(Pearson x2 test), Table 1. Two institutions had a
significantly lower mean age (Tukey–Kramer) than
the others, nursing homes F and G. Median age was
between 82.7 and 87.3 years for all institutions.
Medications in general
The total number of prescriptions recorded was
3468. The average number of regular drugs was
6.1 per patient (n5 513, SD5 3.3, range: 0–20).
Classified according to principal ATC groups
(Skrbo et al., 2004), the three most frequent were
drugs for the ‘nervous system’, ‘digestive organs and
metabolism’ and ‘heart and circulation’ (Table 2).
Paracetamol was the most frequently prescribed
drug (regular and as-needed) with 5.7% (n5 197)
of the total number of prescriptions (n53 468),
administered to 38.4% of the patients.
The average number of as-needed drugs per
patient was 3.8 (n5 513, SD5 2.2, range: 0–14).
Prescriptions of psychoactive drugs by way of
regular or as-needed prescriptions are shown in
Table 3. Of 513 patients, 24.4% (125) were regularly
given one or several neuroleptics, 9.7% (50) of the
patients (n5513) had neuroleptics by way of an as-
needed prescription and 6.4% (8) of the patients on
regular neuroleptics (n5 125) were using two dif-
ferent ones regularly. Risperidone was the most
frequent antipsychotic drug, and haloperidol was
the most frequent as-needed neuroleptic.
Of all, 14.6% (75) of the patients (n5 513)
were on opioids (N02A) by way of regular med-
ication and 28.7% (147) by way of an as-needed
drug, and 41.5% (215) of the patients received
antidepressants as regular medication.
On the basis of our figures, prevalences of long-
term patients in nursing homes being prescribed
psychoactive medication were as follows: neuro-
leptics regular 244/1000 and as-needed 98/1000;
antidepressants regular 419/1000; anxiolytics regular
220/1000 and as-needed 415/1000; and opioids
regular 146/1000 and as-needed 287/1000.
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Table 1 Nursing home characteristics: characteristics of the seven nursing homes with long-term patients participating in the city of Bergen,
Norway, in 2008 (n5513 long-term patients)
Nursing home A B C D E F G Total P
n 83 77 39 85 82 101 46 513
No. of places (total/long/short) 108/88/20 84/63/21 66/31/35 90/90/0 107/81/26 131/99/32 64/48/16 650/500/150
Location in city Suburb Inner city Suburb Suburb Inner city Suburb Suburb
Doctors’ hours per place per week 0.4 0.3 0.5 0.3 0.4 0.4 0.5 0.4 ,0.00011
Men (%) 33.7 33.8 28.2 26.7 21.0 37.6 30.4 30.2 0.27312
Age (years)
Mean 86.7 85.2 84.7 84.9 88.2 79.6 82.2 84.4 0.00013
SD 7.6 10.7 7.5 9.1 6.8 15.7 10.0
Length of stay (days)
Mean 990.0 901.5 973.1 946.1 1728.9 1383.1 1055.2 1171.5 ,0.00014
(6SEM) (6115.8) (6121.8) (6169.0) (6115.8) (117.2) (6106.5) (6169.0)
Median 1102.9 1038.8 747.8 854.7 1071.6 1299.9 873.4
Median test 22.3 21.4 20.5 21.8 4.5 1.0 0.2
Non-demented (%) 20.7 31.6 0.0 29.4 41.4 20.8 19.6 23.4 0.00055
Deviation 23.8 14.7 29.9 13.4 113.2 24.7 22.7
Suffered stroke (%) 29.3 7.9 28.2 34.1 20.7 26.7 13.1 22.8 0.01156
Deviation 14.5 212.1 11.9 19.1 22.2 13.6 24.8
SD5 standard deviation; SEM5 standard error mean.
1 Kruskal–Wallis test.
2 Pearson x2 test.
3–4 Wilcoxon test.
5–6 Pearson x2 test.
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Differences among the nursing homes
We discovered some significant correlations in
the total material that could bias the differences
between nursing homes. Morphine is given less in
the nursing home where the physician was a
specialist (Pearson, P5 0.0097) as were neuro-
leptics (Pearson, P5 0.0139). Neuroleptics were
given more to patients suffering from dementia
(P5 0.0259); fewer benzodiazepines were given
with increasing age (P5 0.0066); the longer the
stay, the fewer the antidementics that were given
(P5 0.0001); and patients on antidepressants
had a lower age (P5 0.0002). However, analyzing
differences among institutions, correcting for
these factors and for age and sex, impacted only
slightly on some P-values, although not on the
total picture.
We discovered significant differences between
nursing homes as a percentage of patients on drugs
within the actual ATC main group. Differences
Table 2 Prescriptions per ATC main groups: ranking of the number of prescriptions according to the classification
of the ATC Drug Register among long-term patients at seven nursing homes in Bergen, Norway (n5513)
Principal ATC group ATC group name No. of prescription %
N Nervous system 1107 31.9
A Digestive organs and metabolism 851 24.5
C Heart and circulation 553 15.9
B Blood and blood-forming organs 389 11.2
R Respiratory organs 140 4.0
H Hormones systemically, without sex hormones and insulin 83 2.4
G Urogenital system and sex hormones 81 2.3
S Sensory organs 80 2.3
M Muscles and skeleton 59 1.7
J Anti-infectants for systemic use 57 1.6
D Dermatological agents 44 1.3
L Antineoplastics and immune modulators 23 0.7
P Antiparasitics 1 0.0
Total number of prescriptions 3468 100.0
ATC5anatomical therapeutic chemical.
Table 3 Psychoactive drugs: ranking of the most prescribed drugs affecting the central nervous system among
513 long-term patients at seven nursing homes in Bergen, Norway
Regular drugs As-needed drugs
ATC code* Drug group Patients
with drug
ATC code Drug group Patients
with drug
n % n %
N06A Antidepressants 215 41.5 N02B Analgesics/antipyretics 227 44.2
N02B Analgesics/antipyretics 206 40.2 N05B Anxiolytics 213 41.5
N05A Antipsychotics 125 24.4 N02A Opioids 147 28.7
N05B Anxiolytics 113 22.0 N05C Hypnotics and sedatives 108 21.1
N05C Hypnotics and sedatives 99 19.3 N05A Antipsychotics 50 9.7
N02A Opioids 75 14.6 N03A Antiepileptics 3 0.6
N06D Antidementics 65 12.7 N06A Antidepressants 3 0.6
N03A Antiepileptics 58 11.3
N04B Dopaminergics (anti-Parkinson’s) 20 3.9
N04A Anticholinergics (anti-Parkinson’s) 9 1.8
N06B Psychostimulants 1 0.2
N02C Migraine drugs 0 0.0
ATC5anatomical therapeutic chemical.
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were highly significant statistically for morphine
(Pearson x2 test, P5 0.0117), neuroleptics
(P5 0.0026) and antidepressants (P5 0.0010),
Table 4. Comparison of drug use among the
patients with reduced cognitive functions by
institution is demonstrated in Figure 1. Differ-
ences between institutions were significant for
neuroleptics (Pearson x2 test, P5 0.0016) and
antidepressants (P5 0.0010) but not for anti-
dementics (P5 0.566).
The addition of DDDs and calculating total
drug use per institution even increased the differ-
ences, and the differences were highly significant for
all drug classes, Table 5 and Figure 2.
Neuroleptics – Parkinsonism
Five out of 18 patients being given drugs for
Parkinsonism were also on neuroleptics. One of
the patients was a psychiatric patient on biper-
iden. One was being given quetiapine, which is an
atypical neuroleptic not contraindicated in the
case of Parkinsonism. Three could be character-
ized as possibly harmful medications. On the basis
of our material, the prevalence of current medi-
cation was 2/1000 among all long-term nursing
home patients.
Medication for patients with impaired cognition
Patients with impaired cognitive function were
prescribed significantly fewer regular drugs than
patients without impairment. The average for
patients without impairment was 7.1 drugs
(n5 130) and for the patients with impaired
cognitive functions 5.7 drugs (n5 381, Wilcoxon
test, P, 0.0001). There was no difference in the
number of as-needed drugs for the two patient
groups. Among patients with impaired cognitive
functions, 21.0% had suffered stroke, and among
patients without impairment 32.0% (OR: 1.76,
95% CI: 1.13–2.75). In general, there was a
tendency to lower the prescription rate of all
cardiovascular drugs for the patients with reduced
Table 4 Institution differences, psychoactive drugs: proportions of long-term patients on one or more regular and
as-needed psychoactive drugs prescribed in seven (A, By) nursing homes in Bergen, Norway, 2008
A B C D E F G P
Morphine regular 0.08 0.13 0.31 0.19 0.18 0.15 0.04 0.0118
Neuroleptics regular 0.36 0.27 0.13 0.32 0.26 0.14 0.15 0.0029
Anxiolytics regular 0.30 0.19 0.26 0.26 0.18 0.23 0.09 0.1111
Hypnotics regular 0.19 0.19 0.18 0.22 0.17 0.19 0.24 0.9677
Antidepressants regular 0.41 0.42 0.49 0.56 0.22 0.40 0.48 0.001
Antidementia regular 0.11 0.14 0.26 0.13 0.07 0.12 0.13 0.2022
Morphine as-needed 0.34 0.27 0.46 0.29 0.34 0.16 0.30 0.0149
Neuroleptics as-needed 0.07 0.08 0.10 0.05 0.21 0.12 0.02 0.0058
Anxiolytics as-needed 0.47 0.42 0.36 0.47 0.30 0.43 0.43 0.3329
Hypnotics as-needed 0.17 0.23 0.23 0.21 0.22 0.23 0.22 0.9644
Antidepressants as-needed 0.00 0.03 0.00 0.00 0.00 0.00 0.02 0.141
Antidementia as-needed na na na na na na na
Figure 1 Use of three different psychoactive drugs
among long-term demented patients at seven nursing
homes (A, By) in Bergen, Norway. Differences between
institutions are significant for neuroleptics (Pearson x2
test, P50.0016) and antidepressants (P50.566). Differences
are not impacted by corrections for age and sex.
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cognitive functions, significantly for angiotensin
converting enzyme inhibitor or angiotensin II
receptor blocker – ACEI/A2B (OR: 1.78, 95%
CI: 1.07–2.94) and diuretics (OR: 1.77, 95% CI:
1.18–2.66). Neuroleptics were more frequently
prescribed to patients with reduced cognitive
functions (31%/21%, OR: 0.58, 95% CI: 0.36–0.94).
ProBNP (brain natriuretic peptide) was signifi-
cantly higher in the patient group without cognitive
impairment (Wilcoxon, P5 0.0011). No such dif-
ferences existed for atrial fibrillation (Pearson x2 test,
P50.137) or renal function (Estimated Glomerular
Filtration Rate, Wilcoxon, P50.1918). Significant
negative correlation was found between age and
weight (Pearson x2 test, P,0.0001), and the average
age among patients with reduced cognitive functions
was lower than the rest of the population (Wilcoxon,
P50.0407). Average patient weight was 62 kg, half
of all patients (n5513) having weight loss last
30 days.
Associations
With regard to comorbidity, we did not find any
associations with the use of neuroleptics and
stroke suffered, or associations between neuro-
leptics and patient weight or weight loss/30 days.
Use of antidepressants was positively associated
with patient weight (Wilcoxon test, P5 0.0037).
No associations for benzodiazepines or hypnotics
were found with stroke, weight or weight loss.
Discussion
The number of drugs given to nursing home patients
in Bergen is higher than the number given 10 years
ago. Considerable treatment rate differences existed
between institutions. Patients with cognitive pro-
blems were prescribed fewer drugs in general but
more neuroleptics. Except for significantly higher
weight in patients on antidepressants, none of the
other clinical factors tested for associations with
psychoactive drugs was significant.
Limitations of the study
The role of nursing homes in the delivery of
social and health care services differs between, as
well as within, countries. Nursing homes in many
countries are managed as part of social care. In
Norway, nursing homes are regulated as a health
care service. These differences may influence the
health issue landscape and composition of staff.
Thus, comparisons and generalizations based on
our findings should be done with care.
For most planned purposes, we consider our
material valid and robust with regard to both
sample size and tested parameters. However, the
size of the material may be too small to calculate
the prevalence of rarer diagnoses/drugs. A weakness
Table 5 Total psychoactive amount (DDD): differences of regularly prescribed psychoactive drugs in seven
nursing homes in Bergen, 2008, expressed by the parameter (total DDD per drug class prescribed)3 (per institution
percentage of patients on drugs of actual class)
A B C D E F G P
Morphine 0.07 0.34 5.21 0.33 0.62 0.34 0.17 ,0.0001
Neuroleptics 4.02 2.76 0.72 9.69 3.06 0.66 0.86 0.0034
Antidepressants 14.89 21.92 28.57 36.74 4.35 17.42 38.71 0.0001
Antidementia drugs 1.32 1.89 5.14 1.75 0.40 1.24 1.51 0.0071
Anxiolytics 2.86 1.56 5.78 2.38 1.73 1.72 0.28 0.0002
Anotics 1.97 2.79 2.31 4.84 2.02 2.64 5.37 0.0001
DDD5Defined Daily Dosages.
Figure 2 Total use (percentages3Defined Daily
Dosage – DDD) for long-term patients on regularly
prescribed psychoactive drugs in seven (A, By) nursing
homes in Bergen, Norway, 2008. Also see Table 5.
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of our study is that comparisons between diagnosis
and drug treatment cannot be performed.
The simple test we used to decide whether or
not patients had reduced cognitive functions can
be questioned (Berger, 1980). Using Minimal
Mental Score was beyond project resources. Our
method was to a certain degree validated, however,
by comparing the extent to which dementia drugs
were given to patients scoring above 0 (reduced
cognitive functions), giving a 95% overlap, and to a
certain degree by medical record data. We thus
found our method sufficient for the purposes
of the study.
Earlier research
We found good concordance with results from
previous studies in terms of the drug groups most
frequently prescribed (N, A, C, B, R; Nygaard, 2001).
In our material, ATC group G (urogenital system
and sex hormones) was used less than previously
demonstrated. References to the use of these drugs
are some years old, and drugs and diagnostics have
evolved, which is probably the reason for this.
The proportion of patients taking neuroleptics
was slightly higher than previously demonstrated
in Bergen nursing homes (23%, 2001). The
decreasing use of neuroleptics in nursing homes
discussed by other authors has not been verified
(Ruths et al., 2001). This is surprising, given
research showing the lack of effect of neuroleptics
among patients suffering dementia. Neuroleptics
are needed in nursing homes, but for limited periods
and for individual patients, and more often than is
currently the case. Patients often end up with a
regular prescription without any evaluation of the
need to pause treatment and take stock after a
period of time (Selbaek et al., 2008).
The use of neuroleptics for patients with Par-
kinson’s is low because of the low prevalence of
Parkinson’s (5.5%); however, the number of these
patients with a drug combination that includes
neuroleptics that are contraindicated is probably
not negligible.
In our study, the prescription of antidepressants
was similar to a comparable study in Bergen in
2001 (Ruths et al., 2001). An increase was
expected. The selective serotonin reuptake inhi-
bitor drugs (SSRIs) are important drugs for the
elderly. Even in our study, we found a positive
association between SSRI use and patient weight.
However, interactions with certain drugs (anti-
epileptics, neuroleptics, cimetidine and codeine)
do exist and they increase the risk of bleeding for
patients on warfarin without impacting the
International Normalized Ratio. Non-steroidal
Anti-inflammatory Drugs together with SSRIs
increase the risk of gastrointestinal bleeding (Van
Der Steen et al., 2009).
Weight gain during antidepressant treatment
can be either a sign of improvement in patients
who have weight loss as a symptom of depression
or a drug side effect. However, significant weight
gain during the acute phase of treatment or
weight gain that continues despite achieving full
remission of depressive symptoms is likely to be
a side effect of antidepressant treatment. Weight
gain is a relatively common problem during both
acute and long-term treatment with antidepressants
(Fava, 2000). In our material, the average patient
weight was 62 kg, half of the patients suffering
weight loss. The unwanted side effect by anti-
depressants in a common population may be an
advantage among nursing home patients. More
research is needed to shed more light on this issue.
However, in our study, the lower age among
patients with reduced cognitive functions may to a
certain degree explain the higher weight in this
group, as weight decreased by age, significantly.
The hazard from falls and fractures when on
psychoactive drugs is well known (Gales and
Menard, 1995; Kiel et al., 2007). In Norway,
, 9000 hip fractures (50% among persons . 85)
are treated in hospitals, giving a yearly age-
independent incidence of 2/1000 and for the
population . 85 , 9/1000 (Van Der Steen et al.,
2009). In Bergen, yearly 90 hip fractures among
2300 nursing home beds were registered over 12
months, 200622007, giving an incidence of 39/1000
(Kru¨ger et al., 2011). The prevalence of hip
fractures has also been estimated by other authors
(Dobnig et al., 2006; Kiel et al., 2007). More differ-
entiation in the use of psychoactive drugs for
patients at risk of falling could prove valuable, like
patients with/without the ability to walk unaided.
A lower cardiovascular drug consumption by
nursing home patients suffering reduced cognitive
functions has been reported by others (Nygaard
et al., 2003). This may reflect a selection effect
as the majority of nursing home patients are
admitted because of dementia (75–80%), and
the others due to somatic illnesses, for example,
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cardiovascular diseases. However, general cardio-
vascular risk factors are also risk factors for devel-
oping Alzheimer’s disease and the combination of
cerebrovascular and degenerative causes make up a
large proportion of all dementias. That ProBNP was
significantly higher among patients without cogni-
tive impairment indicates that morbidity differences
may exist between the two groups, in nursing homes,
with regard to cardiovascular disease. In contrast,
no such differences existed for atrial fibrillation or
renal function. The reasons for lower treatment rate
among patients in nursing homes with impaired
cognitive functions still remain unclear.
Differences between nursing homes
In our study, we have tried to evaluate the
present status and have demonstrated sizable
differences between the nursing homes when it
comes to the use of medications, which cannot be
explained by different prevalences alone. This
was evidenced by our own research on the asso-
ciation between atrial fibrillation and stroke and
warfarin, and it is logical to assume that it obtains
for psychoactive drugs as well (same material,
different publication). Drug differences and phy-
sician staffing have been indicated (Kersten et al.,
2009), but the reasons for such differences are
probably multifactorial, as is quality in general.
Both employee skills and attitudes probably play
a role, as do management, routines, tracking sys-
tems and a collaborative work climate. We did not
see any bias because of sex, age and staffing dif-
ferences between nursing homes or when block-
ing other potentially biasing factors discovered by
multiple regression analysis. Calculating the total
use of drugs within each drug class using DDDs,
increased the differences between institutions,
Table 5 and Figure 1. This probably shows that
institutions with a high percentage use are also
using higher dosages.
Documenting quality status and improving
quality in nursing homes is a challenge. Inter-
nationally, several quality improvement studies
have been undertaken: Nursing homes with a
smaller number of beds, operating for profit and
having a high level of nursing staff may improve
quality (Wan et al., 2006). It has been claimed
that marginalization of physicians in the nursing
home threatens the overall care of increasingly
frail nursing home residents who have medically
complex illnesses (Katz et al., 2009). Medication
quality improvement efforts in nursing homes
should probably focus on the medications com-
monly implicated in errors and should continue to
discourage or closely monitor the use of medica-
tions considered potentially inappropriate in the
elderly (Hansen et al., 2006). A menu-driven
incident-reporting system has the potential to
enhance quality improvement efforts in nursing
homes (Wagner et al., 2005). In pain management,
a multifaceted collaborative intervention proved
valuable, involving audit and feedback on pain
management, education, training, coaching using
rapid-cycle quality improvement techniques and
inter-nursing home collaboration (Baier et al.,
2004). It has been shown that there exists a rela-
tionship between ambitious targets and nursing
home quality (Baier et al., 2009). Implementing
small, focused and inexpensive interventions, like
monitoring BP controls, can improve quality
(Choma et al., 2009).
Simply providing comparative performance
feedback may not be enough to improve resident
outcomes (Rantz et al., 2001). Targeting specific
drugs in the surveyor’s interpretative guidelines
as a method of reducing potentially inappropriate
medication use does not produce the desired
gains in terms of improving the quality of medi-
cation use either (Lapane et al., 2007).
It is difficult to envisage adequate quality con-
trol without the use of modern technology like
medical record systems with alarms, statistics and
decision-making support in addition to already
proven tools for improving the quality of drug
use. The effectiveness of decision support tools
has been shown in several studies and should be
tested in nursing homes (Ornstein et al., 2004;
Kawamoto et al., 2005).
Conclusions
There are differences in treatment with psychoac-
tive drugs between nursing homes. Treatment dif-
ferences also exist between patients with/without
cognitive impairment but reasons remain unclear.
Improvement strategies and more research are
needed. The proportion of patients per institution
on selected drugs can serve as a feedback parameter
in quality systems, but adding DDDs increases
differences.
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